Breast cancer (BC) is the most frequently diagnosed malignant tumor among women worldwide. BC can be treated via surgery, chemotherapy, radiotherapy, hormone therapy, and biological targeted therapies. Due to tumor heterogeneity and multidrug resistance, the overall survival of BC patients still remains suboptimal. Furthermore, the emergence of therapeutic resistance often leads to treatment failure and metastasis of breast cancer.
Metastatic disease is the leading cause of death in BC patients with approximately 90% of deaths resulting from the complications of recurrent or metastatic diseases. Distant metastasis develops in ~20–30% of the early-stage BC patients. Metastatic breast cancer (MBC) most often spreads to the bones, liver, lungs, and brain. Metastasis may develop years after successful primary treatment. The risk of metastasis after BC treatment depends on the biology of the tumor, the stage at the time of the original diagnosis and the treatments used for the original cancer. The search for predictive biomarkers of metastatic relapse is still ongoing. Therefore, identification of the molecular and genetic mechanisms associated with metastasis is vital to improve survival outcomes for patients.
This Research Topic aims to elucidate the molecular mechanisms associated with MBC progression, and identify predictive and prognostic biomarkers of metastatic relapse. We welcome papers on the following topics:
- Predictive and prognostic biomarkers for metastatic relapse
- Molecular and genetic mechanisms in MBC progression
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Breast cancer (BC) is the most frequently diagnosed malignant tumor among women worldwide. BC can be treated via surgery, chemotherapy, radiotherapy, hormone therapy, and biological targeted therapies. Due to tumor heterogeneity and multidrug resistance, the overall survival of BC patients still remains suboptimal. Furthermore, the emergence of therapeutic resistance often leads to treatment failure and metastasis of breast cancer.
Metastatic disease is the leading cause of death in BC patients with approximately 90% of deaths resulting from the complications of recurrent or metastatic diseases. Distant metastasis develops in ~20–30% of the early-stage BC patients. Metastatic breast cancer (MBC) most often spreads to the bones, liver, lungs, and brain. Metastasis may develop years after successful primary treatment. The risk of metastasis after BC treatment depends on the biology of the tumor, the stage at the time of the original diagnosis and the treatments used for the original cancer. The search for predictive biomarkers of metastatic relapse is still ongoing. Therefore, identification of the molecular and genetic mechanisms associated with metastasis is vital to improve survival outcomes for patients.
This Research Topic aims to elucidate the molecular mechanisms associated with MBC progression, and identify predictive and prognostic biomarkers of metastatic relapse. We welcome papers on the following topics:
- Predictive and prognostic biomarkers for metastatic relapse
- Molecular and genetic mechanisms in MBC progression
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.